NYSTATIN ORAL SUSPENSION, USP (100,000 units per mL)

Manufacturer
Precision Dose, Inc.
Effective date
2023-01-25
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
6
Source
legacy-cache
Hydrated at
2026-08-01 21:38:23

Label at a glance#

ProductNystatin
Active ingredientNystatin
Label structure12 sections

Indications and uses

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

Dosage and administration

2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes). NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective. 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be re...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei. Structural formula:

C47H75NO17 MW 926.13
C47H75NO17 MW 926.13

Nystatin Oral Suspension, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤1% v/v), artificial wild cherry flavor, banana flavor, D&C yellow # 10, FD&C red # 40, glycerin, USP, magnesium aluminum silicate, methylparaben, NF, potassium phosphate dibasic, USP, propylene glycol, USP, propylparaben, NF, purified water, USP and sucrose 33.5%. May also contain citric acid, USP for pH adjustment.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Pharmacokinetics

PHARMACOKINETICS SECTION

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

MICROBIOLOGY SECTION

Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candida albicans demonstrates no significant resistance to nystatin in vitro on repeated subculture in increasing levels of nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Pregnancy Category C

SPL UNCLASSIFIED SECTION

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General).

Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

OVERDOSAGE

OVERDOSAGE SECTION

Oral doses of nystatin in excess of five million units daily have caused nausea and gastro intestinal upset. There have been no reports of serious toxic effects of super-infections (see CLINICAL PHARMACOLOGY, Pharmacokinetics).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

INFANTS

SPL UNCLASSIFIED SECTION

2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS

SPL UNCLASSIFIED SECTION

4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.

HOW SUPPLIED

HOW SUPPLIED SECTION

Nystatin Oral Suspension, USP, 100,000 USP Nystatin Units per mL, is available as a fruit flavored, light creamy yellow, ready-to-use suspension.

NDC 68094-599-61
5 mL per unit dose cup
One Hundred (100) cups per shipper

NDC 68094-599-62
5 mL per unit dose cup
Thirty (30) cups per shipper

SHAKE CUPS WELL BEFORE USING

Storage

STORAGE AND HANDLING SECTION

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing.

SPL UNCLASSIFIED SECTION

Rx Only

Manufactured By:
Morton Grove Pharmaceuticals, Inc.
Morton Grove, IL 60053

Manufactured For:
Wockhardt USA, LLC
Parsippany, NJ 07054

Packaged By:
Precision Dose, Inc.
South Beloit, IL 61080

For inquiries call Precision Dose, Inc. at 1-800-397-9228 or email druginfo@precisiondose.com

LI825 Rev. 06/21

PRINCIPAL DISPLAY PANEL - 5 mL Cup Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 68094-599-59

PrecisionDose™

NYSTATIN
Oral Suspension, USP
500,000 units per 5 mL

Pkg: Precision Dose, Inc., S. Beloit, IL 61080

PRINCIPAL DISPLAY PANEL - 5 mL Cup Label
PRINCIPAL DISPLAY PANEL - 5 mL Cup Label

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
68094-599-58ML - Milliliter68094-599fe4c5e77-539a-48b8-9670-2289436110c112012-07-24
68094-599-59ML - Milliliter68094-5993f13beeb-08f4-487c-9f7a-7d85df700b2f12012-07-24
68094-599-61ML - Milliliter68094-599a1fc89af-e887-4bbe-ac2a-e6f648d23dc612012-07-24
68094-599-62ML - Milliliter68094-5991390113c-4118-4d30-b644-756c980b917012012-07-24
60432-537-16ML - Milliliter60432-5374cade063-c2f1-481b-8ce0-2f183b5989df12012-07-24
60432-537-60ML - Milliliter60432-537a627d2f6-c5a2-4e15-80fc-69e008e6482b12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
NystatinACTIVE INGREDIENTBDF1O1C72E2
NystatinACTIVE MOIETYBDF1O1C72E2
alcoholINACTIVE INGREDIENT3K9958V90M2
D&C yellow no. 10INACTIVE INGREDIENT35SW5USQ3G2
FD&C red no. 40INACTIVE INGREDIENTWZB9127XOA2
glycerinINACTIVE INGREDIENTPDC6A3C0OX2
magnesium aluminum silicateINACTIVE INGREDIENT6M3P64V0NC2
methylparabenINACTIVE INGREDIENTA2I8C7HI9T2
potassium phosphate, dibasicINACTIVE INGREDIENTCI71S98N1Z2
propylene glycolINACTIVE INGREDIENT6DC9Q167V32
propylparabenINACTIVE INGREDIENTZ8IX2SC1OH2
sucroseINACTIVE INGREDIENTC151H8M5542
waterINACTIVE INGREDIENT059QF0KO0R2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68094-59968094-599-59, 68094-599-62, 68094-599-61, 68094-599-58
60432-537

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 9 · 494 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
propylparabenPROPYLPARABENZ8IX2SC1OHSOLUTION / RESPIRATORY (INHALATION)0.01 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
sucroseSUCROSEC151H8M554INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS2000 mgExact identifier — unii candidate
48 equally ranked IID candidates
D&C yellow no. 10D&C YELLOW NO. 1035SW5USQ3GGEL / DENTALNAExact identifier — unii candidate
31 equally ranked IID candidates
alcoholALCOHOL3K9958V90MAEROSOL, METERED / RESPIRATORY (INHALATION)26664 mgExact identifier — unii candidate
59 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION / OPHTHALMIC1 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TINJECTION, SOLUTION / PARENTERAL30 mgExact identifier — unii candidate
79 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3OINTMENT / TOPICAL5148 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SPRAY / NASAL5 mgExact identifier — unii candidate
81 equally ranked IID candidates
alcoholALCOHOL3K9958V90MINJECTION / INTRAMUSCULAR1491 mgExact identifier — unii candidate
59 equally ranked IID candidates
FD&C red no. 40FD&C RED NO. 40WZB9127XOACONCENTRATE / ORAL0.04 mg/1mlExact identifier — unii candidate
28 equally ranked IID candidates
FD&C red no. 40FD&C RED NO. 40WZB9127XOACAPSULE, LIQUID FILLED / ORAL1 mgExact identifier — unii candidate
28 equally ranked IID candidates
D&C yellow no. 10D&C YELLOW NO. 1035SW5USQ3GSYRUP / ORAL4 mgExact identifier — unii candidate
31 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TCREAM / VAGINAL22 mgExact identifier — unii candidate
79 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TDROPS / ORAL1 mg/1mlExact identifier — unii candidate
79 equally ranked IID candidates
sucroseSUCROSEC151H8M554LOZENGE / BUCCALNAExact identifier — unii candidate
48 equally ranked IID candidates
D&C yellow no. 10D&C YELLOW NO. 1035SW5USQ3GTABLET / ORAL80 mgExact identifier — unii candidate
31 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TSUSPENSION / ORAL388 mgExact identifier — unii candidate
79 equally ranked IID candidates
sucroseSUCROSEC151H8M554PASTILLE / ORAL426 mgExact identifier — unii candidate
48 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSUSPENSION/ DROPS / OPHTHALMIC2.5 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHFILM, SOLUBLE / BUCCAL1 mgExact identifier — unii candidate
68 equally ranked IID candidates
magnesium aluminum silicateMAGNESIUM ALUMINUM SILICATE6M3P64V0NCOINTMENT / VAGINAL231 mgExact identifier — unii candidate
17 equally ranked IID candidates
alcoholALCOHOL3K9958V90MCONCENTRATE / ORAL198 mgExact identifier — unii candidate
59 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TJELLY / TOPICAL420 mgExact identifier — unii candidate
79 equally ranked IID candidates
D&C yellow no. 10D&C YELLOW NO. 1035SW5USQ3GCAPSULE, DELAYED RELEASE / ORAL1 mgExact identifier — unii candidate
31 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSOLUTION / ORAL32400 mgExact identifier — unii candidate
75 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSPONGE / TOPICAL2 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXGUM, CHEWING / BUCCAL230 mgExact identifier — unii candidate
75 equally ranked IID candidates
D&C yellow no. 10D&C YELLOW NO. 1035SW5USQ3GCAPSULE, COATED PELLETS / ORAL0.01 mgExact identifier — unii candidate
31 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TCAPSULE, EXTENDED RELEASE / ORAL2 mgExact identifier — unii candidate
79 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSUSPENSION / AURICULAR (OTIC)0.05 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3FILM / BUCCAL1.48 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION / AURICULAR (OTIC)56.55 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
alcoholALCOHOL3K9958V90MSOLUTION, CONCENTRATE / ORAL150.68 mg/1mlExact identifier — unii candidate
59 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3INJECTION / INTRAMUSCULAR7459 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3CREAM / TOPICAL76000 mgExact identifier — unii candidate
81 equally ranked IID candidates
sucroseSUCROSEC151H8M554SUPPOSITORY / RECTALNAExact identifier — unii candidate
48 equally ranked IID candidates
magnesium aluminum silicateMAGNESIUM ALUMINUM SILICATE6M3P64V0NCLIQUID / ORAL82 mg/5mlExact identifier — unii candidate
17 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXTABLET / PERIODONTAL0.53 mgExact identifier — unii candidate
75 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXAEROSOL, FOAM / TOPICAL21 mgExact identifier — unii candidate
75 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TINJECTION / PARENTERAL18 mgExact identifier — unii candidate
79 equally ranked IID candidates
potassium phosphate, dibasicDIBASIC POTASSIUM PHOSPHATECI71S98N1ZSOLUTION / ORAL890 mgExact identifier — unii candidate
8 equally ranked IID candidates
D&C yellow no. 10D&C YELLOW NO. 1035SW5USQ3GPOWDER, FOR SUSPENSION / ORAL76 mgExact identifier — unii candidate
31 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION / RESPIRATORY (INHALATION)25 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / TOPICAL5.28 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHINJECTION, SUSPENSION / INTRAMUSCULAR0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TSUPPOSITORY / VAGINALNAExact identifier — unii candidate
79 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TSOLUTION / INTRAVENOUS0.13 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION, CONCENTRATE / ORAL2590 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHINJECTION / INTRALESIONAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
FD&C red no. 40FD&C RED NO. 40WZB9127XOACAPSULE, EXTENDED RELEASE / ORAL1 mgExact identifier — unii candidate
28 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION / TOPICAL4974 mgExact identifier — unii candidate
81 equally ranked IID candidates
alcoholALCOHOL3K9958V90MSPRAY / TOPICAL3633 mgExact identifier — unii candidate
59 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TSOLUTION / INTRAMUSCULAR0.13 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
sucroseSUCROSEC151H8M554INJECTION, EMULSION / INTRAVENOUS970 mgExact identifier — unii candidate
48 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3CAPSULE, COATED / ORAL25 mgExact identifier — unii candidate
81 equally ranked IID candidates
D&C yellow no. 10D&C YELLOW NO. 1035SW5USQ3GPOWDER, FOR SOLUTION / ORALNAExact identifier — unii candidate
31 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXINJECTION, SOLUTION / INTRAMUSCULAR15 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXGEL / OPHTHALMIC0.88 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
sucroseSUCROSEC151H8M554LIQUID / ORAL37500 mgExact identifier — unii candidate
48 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TSUSPENSION / SUBCUTANEOUS0.16 %w/vExact identifier — unii candidate
79 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062512-001NYSTATINNYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A062512-001AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29d4dbc9d85df4…
2026-10-15 13:18:302026-09A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29c2088c7a36db…
2026-09-14 22:38:342026-08A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-2984e616aacf4f…
2026-08-18 06:07:402026-07A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-2987673890dc5c…
2021-03-12 10:30 UTC2021-03A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-293f01610625f2…
2019-09-15 20:21 UTC2019-09A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29b00525d2431f…
2019-07-19 19:46 UTC2019-07A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-293bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A062512-001AA1d4dbc9d85df4…
2026-10-15 13:18:302026-09A062512-001AA1c2088c7a36db…
2026-09-14 22:38:342026-08A062512-001AA184e616aacf4f…
2026-08-18 06:07:402026-07A062512-001AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062512-001AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062512-001AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A062512-001AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062512-001AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062512-001AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062512-001AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062512-001AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062512-001AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062512-001AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062512-001AA1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062512-001AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062512-001AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062512-001AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062512-001AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062512-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062512-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062512-001AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062512-001AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062512-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062512-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062512-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A062512-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062512-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062512-001AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062512-001AA13f01610625f2…
2019-09-15 20:21 UTC2019-09A062512-001AA1b00525d2431f…
2019-07-19 19:46 UTC2019-07A062512-001AA1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062512-001AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062512-001AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062512-001AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062512-001AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062512-001AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062512-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062512-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A062512-001AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01A062512-001AA13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
86bf7f7b-cb8b-4592-98f3-c8733cd080f929a5391d-6db4-4226-82ed-4481b3e445c82023-01-25Adverse reactionsExact identifier
spl id: 86bf7f7b-cb8b-4592-98f3-c8733cd080f9
spl set id: 29a5391d-6db4-4226-82ed-4481b3e445c8

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.